Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2022.2424
Abstract: Importance Treatment of newly diagnosed multiple myeloma (NDMM) with a quadruplet regimen consisting of a monoclonal antibody, proteasome inhibitor, immunomodulatory imide, and corticosteroid has been associated with improved progression-free survival (PFS) compared with triplet regimens.… read more here.
Keywords: mrd negativity; elotuzumab weekly; elo krd; mrd ... See more keywords
Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia research"
DOI: 10.1016/j.leukres.2019.106283
Abstract: Minimal residual disease (MRD) negativity is a key prognostic indicator of outcome in acute lymphocytic leukemia. In the INO-VATE trial (clinicaltrials.gov identifier: NCT01564784), patients with relapsed/refractory acute lymphocytic leukemia who received inotuzumab versus standard chemotherapy… read more here.
Keywords: relapsed refractory; refractory acute; mrd negativity; patients relapsed ... See more keywords
Real‐world data on prognostic value of measurable residual disease assessment by fragment analysis or next‐generation sequencing in multiple myeloma
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18211
Abstract: Measurable residual disease (MRD) negativity is a strong prognostic indicator in multiple myeloma (MM). However, the optimal use of MRD in daily clinical practice has been hampered by the limited feasibility of MRD testing. Therefore,… read more here.
Keywords: mrd; measurable residual; mrd negativity; fragment analysis ... See more keywords
Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Internal Medicine"
DOI: 10.1111/joim.12590
Abstract: In the USA at the beginning of this century, the average overall survival in patients with multiple myeloma was about 3 years. Around that time, three drugs (bortezomib, lenalidomide and thalidomide) were introduced for the… read more here.
Keywords: combination; treatment; multiple myeloma; mrd negativity ... See more keywords
The MRD-Negativity Rate Measured By Flow Cytometry after the 1st and the 2nd Induction Course Among CR AML Patients from Different Cytogenetic Subgroups Does Not Differ Though the Morphological CR Achievement Does
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-116581
Abstract: Background. The recent ELN recommendations (2017) have introduced new criteria of response in AML - complete remission with MRD-negativity (CR/MRD-neg). It's a well-known fact that AML with different cytogenetics has different chemosensitivity, and so -… read more here.
Keywords: risk; induction; rate; mrd negativity ... See more keywords
Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-124191
Abstract: Introduction: Achievement of MRD negativity in MM is associated with prolonged progression-free survival (PFS) and is being investigated as a potential surrogate for established clinical endpoints, such as PFS and overall survival (OS). Here, we… read more here.
Keywords: pfs; mrd; mrd negativity; employment ... See more keywords
Impact of Minimal Residual Disease Analysis in the Era of Rituximab Maintenance in Follicular Lymphoma: Data from “FOLL12” Phase III Trial of the Fondazione Italiana Linfomi
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194832
Abstract: Introduction. Minimal residual disease (MRD) analysis has been largely used in follicular lymphoma (FL) for outcome prediction. However, despite the broad employment of rituximab maintenance for long-term disease control, there are few published data describing… read more here.
Keywords: disease; maintenance; mrd; mrd negativity ... See more keywords
MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200210
Abstract: Background and Significance: Autologous hematopoietic cell transplantation (AHCT) is essential for eligible patients with newly diagnosed multiple myeloma (NDMM) but associated with short-term toxicities and long term risks of genetic instability and second primary malignancies.… read more here.
Keywords: maintenance; therapy; mrd; mrd negativity ... See more keywords
Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-200395
Abstract: Background: Epcor, a subcutaneous CD3xCD20 bispecific antibody, is approved as monotherapy for adults with relapsed or refractory DLBCL after ≥2 lines of systemic therapy. Combining epcor with antineoplastic agents that have complementary mechanisms of action… read more here.
Keywords: treatment; pola; mrd negativity; epcor ... See more keywords
Circulating Tumor DNA As a Minimally Invasive Predictor of Early Relapse in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-204426
Abstract: Background: Achieving minimal residual disease (MRD) negativity in multiple myeloma (MM) is associated with improved progression-free (PFS) and overall survival (OS). However, current MRD assessment relies on invasive bone marrow biopsies and cannot detect extramedullary… read more here.
Keywords: sustained mrd; tumor; mrd negativity; tumor dna ... See more keywords
Measurable Residual Disease (MRD) Determinants, Kinetics and Its Impact on Survival in Patients Treated with Azacitidine and Venetoclax for Acute Myeloid Leukemia in Frontline Setting : A Multicentric Study from French Auraml Group
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-207764
Abstract: In intensively treated acute myeloid leukemia (AML) patients, measurable residual disease (MRD) has become a critical standardized endpoint which is highly predictive of relapse-free (RFS) and overall (OS)survival. Azacitidine and venetoclax (AZA/VEN) combination regimen recently… read more here.
Keywords: mprs; aza ven; risk; mrd ... See more keywords